KR20230120627A - Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법 - Google Patents

Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법 Download PDF

Info

Publication number
KR20230120627A
KR20230120627A KR1020237005090A KR20237005090A KR20230120627A KR 20230120627 A KR20230120627 A KR 20230120627A KR 1020237005090 A KR1020237005090 A KR 1020237005090A KR 20237005090 A KR20237005090 A KR 20237005090A KR 20230120627 A KR20230120627 A KR 20230120627A
Authority
KR
South Korea
Prior art keywords
solution
solid phase
amount
target
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005090A
Other languages
English (en)
Korean (ko)
Inventor
요시오 혼다
타쿠 이토
준 이치노세
히로아키 이치카와
토모유키 이마이
코타로 나가츠
히사시 스즈키
Original Assignee
니혼 메디피직스 가부시키가이샤
내셔널 인스티튜츠 포 퀀텀 사이언스 앤드 테크놀로지
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 니혼 메디피직스 가부시키가이샤, 내셔널 인스티튜츠 포 퀀텀 사이언스 앤드 테크놀로지 filed Critical 니혼 메디피직스 가부시키가이샤
Publication of KR20230120627A publication Critical patent/KR20230120627A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/12—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by a special physical form, e.g. emulsion, microcapsules, liposomes, characterized by a special physical form, e.g. emulsions, dispersions, microcapsules
    • A61K51/121—Solutions, i.e. homogeneous liquid formulation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • G—PHYSICS
    • G21—NUCLEAR PHYSICS; NUCLEAR ENGINEERING
    • G21G—CONVERSION OF CHEMICAL ELEMENTS; RADIOACTIVE SOURCES
    • G21G4/00—Radioactive sources
    • G21G4/04—Radioactive sources other than neutron sources
    • G21G4/06—Radioactive sources other than neutron sources characterised by constructional features
    • G21G4/08—Radioactive sources other than neutron sources characterised by constructional features specially adapted for medical application

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Immunology (AREA)
  • Dispersion Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Engineering & Computer Science (AREA)
  • High Energy & Nuclear Physics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020237005090A 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법 Pending KR20230120627A (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
JP2021002437 2021-01-08
JPJP-P-2021-002437 2021-01-08
PCT/JP2022/000116 WO2022149578A1 (ja) 2021-01-08 2022-01-05 Ａｃ－２２５溶液の製造方法およびＡｃ－２２５溶液を用いた医薬の製造方法
KR1020227021372A KR102500942B1 (ko) 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020227021372A Division KR102500942B1 (ko) 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법

Publications (1)

Publication Number Publication Date
KR20230120627A true KR20230120627A (ko) 2023-08-17

Family

ID=82357768

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020237005090A Pending KR20230120627A (ko) 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법
KR1020227021372A Active KR102500942B1 (ko) 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227021372A Active KR102500942B1 (ko) 2021-01-08 2022-01-05 Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법

Country Status (10)

Country Link
US (2) US11752223B2 (https=)
EP (1) EP4276855A4 (https=)
JP (2) JP7154465B1 (https=)
KR (2) KR20230120627A (https=)
CN (1) CN116711028A (https=)
AU (1) AU2022206140A1 (https=)
CA (1) CA3207700A1 (https=)
TW (1) TW202235093A (https=)
WO (1) WO2022149578A1 (https=)
ZA (1) ZA202306906B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230390425A1 (en) * 2020-10-16 2023-12-07 Nihon Medi-Physics Co., Ltd. Radioactive complexes of anti-her2 antibody, and radiopharmaceutical
WO2026063503A1 (ja) * 2024-09-20 2026-03-26 日本メジフィジックス株式会社 Ａｃ－２２５溶液の製造方法および該溶液を用いたＡｃ－２２５標識錯体の製造方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502965A (ja) 2006-09-08 2010-01-28 アクチニウム ファーマシューティカルズ，インコーポレイティド 種々の供給源からのラジウムの精製方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH07203974A (ja) 1994-01-13 1995-08-08 Tosoh Corp 癌特異的ムチンを認識する抗体の遺伝子断片等
JPH115749A (ja) 1997-06-13 1999-01-12 Tosoh Corp 癌治療医薬品組成物
US6670456B2 (en) * 2001-02-28 2003-12-30 Dow Global Technologies Inc. Actinium-225 complexes and conjugates for targeted radiotherapy
US7087206B2 (en) * 2002-04-12 2006-08-08 Pg Research Foundation Multicolumn selectivity inversion generator for production of high purity actinium for use in therapeutic nuclear medicine
ES2524767T3 (es) * 2002-06-14 2014-12-12 Immunomedics, Inc. Anticuerpo monoclonal humanizado HPAM4
DE10347459B3 (de) 2003-10-13 2005-05-25 Actinium Pharmaceuticals, Inc. Radium-Target sowie Verfahren zu seiner Herstellung
WO2005084179A2 (en) * 2003-12-01 2005-09-15 Immunomedics, Inc. Improved method for preparing conjugates of proteins and chelating agents
DE102006042191B4 (de) * 2005-09-09 2010-08-05 Actinium Pharmaceuticals, Inc. Verfahren zur Reinigung von Radium aus verschiedenen Quellen
DE102006008023B4 (de) * 2006-02-21 2008-05-29 Actinium Pharmaceuticals, Inc. Verfahren zum Reinigen von 225Ac aus bestrahlten 226Ra-Targets
WO2013157102A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
WO2013157105A1 (ja) 2012-04-18 2013-10-24 公立大学法人大阪市立大学 ムチンサブタイプ５ａｃ特異的ヒト化抗体およびその利用
DE102014115154A1 (de) * 2014-10-17 2016-04-21 SCV-SpezialChemikalien-Vertrieb GmbH Konjugierte Bisphosphonate für die Diagnostik und Therapie von Knochenerkrankungen
ES3058443T3 (es) 2015-05-20 2026-03-10 Univ Kagoshima Modificación específica de anticuerpo con péptido de unión a IgG
DK3470418T3 (da) 2016-06-13 2024-09-30 Univ Kagoshima Site-specifik radioisotop-mærket antistof ved brug af using iggbindende peptid
EA202090056A1 (ru) * 2017-06-29 2020-04-13 Зе Саус Африкан Нюклиар Энерджи Корпорейшен Сок Лимитед Получение радиоизотопов
KR102924918B1 (ko) 2019-06-19 2026-02-10 니혼 메디피직스 가부시키가이샤 226Ra 타깃의 제조 방법, 225Ac의 제조 방법 및 226Ra 타깃 제조용 전착액
WO2021002275A1 (ja) * 2019-07-02 2021-01-07 日本メジフィジックス株式会社 ２２６Ｒａ含有溶液の精製方法、２２６Ｒａターゲットの製造方法および２２５Ａｃの製造方法
CA3148288A1 (en) 2019-08-21 2021-02-25 Nihon Medi-Physics Co., Ltd. Method for producing radioactive metal complex
JPWO2021075546A1 (https=) 2019-10-18 2021-04-22

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2010502965A (ja) 2006-09-08 2010-01-28 アクチニウム ファーマシューティカルズ，インコーポレイティド 種々の供給源からのラジウムの精製方法

Also Published As

Publication number Publication date
EP4276855A4 (en) 2025-08-06
JPWO2022149578A1 (https=) 2022-07-14
EP4276855A1 (en) 2023-11-15
US20230364275A1 (en) 2023-11-16
AU2022206140A1 (en) 2023-07-27
CA3207700A1 (en) 2022-07-14
US11752223B2 (en) 2023-09-12
ZA202306906B (en) 2024-10-30
JP2022188190A (ja) 2022-12-20
WO2022149578A1 (ja) 2022-07-14
TW202235093A (zh) 2022-09-16
CN116711028A (zh) 2023-09-05
JP7846599B2 (ja) 2026-04-15
KR20220101191A (ko) 2022-07-19
US20220370651A1 (en) 2022-11-24
JP7154465B1 (ja) 2022-10-17
KR102500942B1 (ko) 2023-02-17

Similar Documents

Publication Publication Date Title
KR102500942B1 (ko) Ac-225 용액의 제조 방법 및 Ac-225 용액을 사용한 의약의 제조 방법
US11986815B2 (en) Processes and systems for producing and/or purifying gallium-68
RU2542733C1 (ru) Способ получения радиоизотопа лютеций-177
KR20220083768A (ko) 방사성 금속 표지 항체의 제조 방법
US20180158559A1 (en) Method and system for producing gallium-68 radioisotope by solid targeting in a cyclotron
RU2768732C2 (ru) Способ получения изотопа
JP2009229201A (ja) Ｇａのイオンを単離する方法とそのための装置
RU2852721C1 (ru) СПОСОБ ПОЛУЧЕНИЯ РАСТВОРА Ac-225 и СПОСОБ ПОЛУЧЕНИЯ ЛЕКАРСТВЕННОГО ПРЕПАРАТА С ИСПОЛЬЗОВАНИЕМ РАСТВОРА Ac-225
KR101451907B1 (ko) 역상 액체크로마토그래피를 이용한 루테튬-177의 분리방법
WO2018074918A1 (en) Isomeric transition radionuclide generator, such as a 177mlu/177lu generator
JP5376130B2 (ja) 抗体標識が可能な無担体１７７Ｌｕの分離精製法
CN118891277A (zh) 复合体的制造方法
KR100906781B1 (ko) Ｃｕ-64를 Ｇａ-67 생성물의 폐기물로부터 생산하는 방법
Nordell et al. Production of 123I by photonuclear reactions on Xenon
Watanabe et al. Improvement and optimization of clinically potent positron emitter 76Br isolation using the dry distillation approach for its future automation
Valdovinos et al. Simplified and reproducible radiochemical separations for the production of high specific activity 61Cu, 64Cu, 86Y and 55Co
RU2803641C1 (ru) Способ получения радиоизотопа тербий-161
RU2734429C1 (ru) Способ получения генераторного радионуклида Pb-212 для производства терапевтического препарата на основе радионуклида Bi-212
WO2026063503A1 (ja) Ａｃ－２２５溶液の製造方法および該溶液を用いたＡｃ－２２５標識錯体の製造方法
Kolevska et al. Zirconium-89 labeled antibodies: general considerations towards radioisotope production and labelling strategies
CN117377696A (zh) 用放射β射线的核素标记的人源化抗体
HK40076208A (en) Method for producing radioactive metal-labeled antibody
Satoh et al. Preparation of Carrier-Free Strontium Isotopes

Legal Events

Date Code Title Description
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20230213

Application number text: 1020227021372

Filing date: 20220623

PG1501 Laying open of application